

Amendments to the Claims:

1-87. (canceled)

88. (currently amended) A An isolated polynucleotide encoding at least one monomer of a non-oligomerizing tandem fluorescent protein, wherein the non-oligomerizing tandem fluorescent protein comprises a first monomer of a green fluorescent protein (GFP) or a fluorescent protein related to a GFP operatively linked to at least a second monomer of the a GFP fluorescent protein or fluorescent protein related to a GFP, wherein the propensity of the tandem fluorescent protein to oligomerize form intermolecular oligomers is reduced or inhibited as compared to a monomer of the a GFP fluorescent protein or a fluorescent protein related to a GFP.

89-92. (canceled)

93. (currently amended) The isolated polynucleotide of claim ~~89~~ 88, wherein the fluorescent protein is an *Aequorea* GFP, ~~a Renilla GFP, a Phialidium GFP, or a fluorescent protein related to an Aequorea GFP, a Renilla GFP, and a Phialidium GFP.~~

94. (currently amended) The isolated polynucleotide of claim 93, wherein the fluorescent protein related to the *Aequorea* GFP is a an enhanced cyan fluorescent protein (CFP), ~~or a yellow fluorescent protein (YFP), or a spectral variant of the CFP or the YFP.~~

95. (currently amended) The isolated polynucleotide of claim 93, wherein the fluorescent protein related to the *Aequorea* GFP is ~~an enhanced GFP (EGFP; SEQ ID NO: 4), an enhanced CFP (ECFP; SEQ ID NO: 6), or an EYFP-V68L/Q69K (SEQ ID NO: 10), or an enhanced YFP (EYFP; SEQ ID NO: 8).~~

96. (currently amended) The isolated polynucleotide of claim 88, wherein the fluorescent protein further comprises a mutation of an amino acid residue corresponding to A206, L221, F223, or a combination thereof of SEQ ID NO: 2.

97. (currently amended) The isolated polynucleotide of claim 96, wherein the mutation corresponds to an A206K mutation, an L221K mutation, an F223R mutation, or an L221K and F223R mutation of SEQ ID NO: 2.

98. (currently amended) The isolated polynucleotide of claim 97 ~~96~~, wherein the mutation corresponds to an A206K mutation, an L221K mutation, an F223R mutation, or an L221K and F223R mutation of SEQ ID NO: 6 or SEQ ID NO: 10.

99. (currently amended) The isolated polynucleotide of claim 88, wherein the first monomer and the second monomer are operatively linked using a peptide linker.

100-101. (canceled)

102. (currently amended) The isolated polynucleotide of claim 88, further comprising at least a third monomer of the fluorescent protein, which is operatively linked to the first monomer or the second monomer.

103. (currently amended) A An isolated polynucleotide encoding at least one monomer of a fusion protein, wherein the fusion protein comprises the non-oligomerizing tandem fluorescent protein of claim 88 operatively linked to at least one polypeptide of interest.

104. (currently amended) The isolated polynucleotide of claim 103, wherein the non-oligomerizing tandem fluorescent protein is linked to the polypeptide of interest through a peptide bond.

105. (currently amended) The isolated polynucleotide of claim ~~104~~ 103, wherein the non-oligomerizing tandem fluorescent protein is linked to the polypeptide of interest through a linker molecule.

106. (currently amended) The isolated polynucleotide of claim 103, wherein ~~the~~ at least one polypeptide of interest comprises a peptide tag.

107. (currently amended) The isolated polynucleotide of claim 106, wherein the peptide tag is a polyhistidine peptide.

108. (currently amended) The isolated polynucleotide of claim 103, wherein the polypeptide of interest is a cellular polypeptide.

109. (currently amended) The isolated polynucleotide of claim 103, wherein the polypeptide of interest is an enzyme, a G-protein, a growth factor receptor, or a transcription factor.

110. (currently amended) The isolated polynucleotide of claim 103, wherein the polypeptide of interest is one of two or more proteins that associate to form a complex.

111-127. (canceled)

128. (currently amended) A vector comprising the isolated polynucleotide of claim 88.

129-133. (canceled)

134. (currently amended) A host cell comprising the isolated polynucleotide of claim 88.

135-137. (canceled)

138. (currently amended) A kit comprising at least one isolated polynucleotide of claim 88.

139-153. (canceled)

CONCLUSION


Applicants respectfully submit that, upon replacement of the "Amendments to the Claims" section of the Amendment and Response that was filed on August 22, 2003 with the "Amendments to the Claims" section presented in the present Supplementary Amendment, the amendments to the claims will be in compliance with the requirements of 37 C.F.R. § 1.121. Applicants respectfully request reconsideration and allowance of claims 88, 89, 93-99, 102-110, 128, 134, and 138.

Although no fees are believed to be due at this time, please charge any fees, including any fees for extension of time, or credit overpayment to Deposit Account No. 08-1641 referencing Attorney's Docket No. 39754-0831 CP2.

Respectfully submitted,

Date: September 10, 2003

By:



James A. Fox (Reg. No. 38,455)

Heller Ehrman White & McAuliffe LLP
275 Middlefield Road
Menlo Park, California 94025-3506
Telephone: (650) 324-6951
Facsimile: (650) 324-6654

SY 454658 v1
9/10/03 9:26 AM (39754.0831)

RECEIVED
CENTRAL FAX CENTER

SEP 10 2003

OFFICIAL